# Why the two LIVERAGE studies use different liver outcomes

- Article ID: research-358
- Product: Survodutide (survodutide-700)
- Canonical page: https://heritagebiolabs.com/research-library/articles/358-why-the-two-liverage-studies-use-different-liver-outcomes
- Product collection: https://heritagebiolabs.com/research-library/products/survodutide
- Product page: https://heritagebiolabs.com/product/survodutide-700
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains connected by peptide bonds. A designed peptide can activate receptors involved in how the body uses and stores nutrients. Survodutide is an investigational peptide that acts on the glucagon and GLP-1 receptors. The LIVERAGE registry records describe two trials that ask different questions about liver disease at different stages of scarring. [1, 2, 3]

One trial enrolls adults with metabolic dysfunction-associated steatohepatitis, or MASH, and moderate to advanced scarring without cirrhosis. Its first part lists outcomes based on the appearance of liver tissue. One asks whether MASH resolves without worsening scarring. Another asks whether scarring improves by at least one stage without MASH getting worse. The paired conditions keep the two features of liver disease in view. [1]

The other trial studies people who already have compensated cirrhosis due to MASH. In compensated cirrhosis the liver has extensive scarring but continues to perform its major functions without the specified complications that mark decompensation. The registry’s main outcome combines clinical events and disease progression measures over a longer period. Examples include a liver transplant, decompensation or progression to a level of pressure in the liver’s blood vessels that the protocol defines as clinically significant. [2]

Both records were updated in October 2026 and listed no posted results. The records describe who the investigators plan to study and which outcomes will be compared. They do not provide estimates of benefit or risk. By using different outcomes for different stages of disease, the two trials can address distinct questions about what happens to liver tissue and what happens to people over time. [1, 2]

## Sources

1. Boehringer Ingelheim. A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis. ClinicalTrials.gov (publication 2024-10-09, record updated 2026-10-28). <https://clinicaltrials.gov/study/NCT06632444>
2. Boehringer Ingelheim. A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis. ClinicalTrials.gov (publication 2024-10-09, record updated 2026-10-28). <https://clinicaltrials.gov/study/NCT06632457>
3. Arun J. Sanyal et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England Journal of Medicine (publication 2024-06-07). <https://pubmed.ncbi.nlm.nih.gov/38847460/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 072 - SNAP-8 and Survodutide.docx; article 358; content SHA-256 297cccf9ebd0295ad3602c4f35d422a9d37bff7980947c0f3f970f0cc7480660.
